account_id none on file
legal_name Innate Pharma SA
ticker IPHA
cik 1598599
domain innate-pharma.com
linkedin_company_url https://www.linkedin.com/company/innate-pharma
entry_point_account_id none on file
name Innate Pharma S.A.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 14 executives 8 family 0
why_nownone on file
callsnone on file
filings
Selling, general and administrative expenses also consist of fees for professional services, mainly related to audit, IT, accounting, recruitment and legal services, communication and travel costs, real-estate leasing costs, office furniture and equipment costs, allowance for amortization and depreciation, director’s attendance fees and insurance costs and overhead costs, such as postal and telecommunications expense
filing / Apr 1, 2026 / receipt
In case of urgency, the initiator of the consultation may set a shorter period for lodging objections. The consultation shall take the form of a draft set of minutes expressly stating that it is a written consultation, together with the documents necessary for the decision-making process.
filing / Apr 1, 2026 / receipt
Cost containment measures that healthcare payors and providers are instituting and the effect of further healthcare reform could significantly reduce potential revenues from the sale of any of its product candidates approved in the future, and could cause an increase in its compliance, manufacturing, or other operating expenses.
filing / Apr 1, 2026 / receipt
A primary trend in the United States healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals and changes during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for biologics and other medical products, government control and other changes to the healthcare system in the United States.
filing / Apr 1, 2026 / receipt
Indirect research and development expenses decreased primarily due to lower personnel costs (excluding restructuring charges of €2.3 million), reduced scientific consulting fees, lower depreciation and amortization, and a decrease in intellectual property expenses, partially offset by restructuring charges associated with the implementation of the Workforce Restructuring Plan (Plan de Sauvegarde de l’Emploi).
filing / Apr 1, 2026 / receipt
Personnel expenses remained stable despite €0.6 million in restructuring charges resulting from the implementation of the Workforce Restructuring Plan.
filing / Apr 1, 2026 / receipt
Olivier Martinez | 55 | Member of the Board of Directors
filing / Apr 1, 2026 / receipt
Pascale Boissel | 59 | Vice Chairwoman of the Board of Directors
filing / Apr 1, 2026 / receipt
Christian Itin | 62 | Member of the Board of Directors
filing / Apr 1, 2026 / receipt
Marty J. Duvall | 64 | Member of the Board of Directors
filing / Apr 1, 2026 / receipt
Sally Bennett | 54 | Member of the Board of Directors
filing / Apr 1, 2026 / receipt
Odile Belzunce | 45 | Member of the Leadership Team, VP Compliance, IT and Portfolio Management
filing / Apr 1, 2026 / receipt
executives
| Christian Itin | Member of the Board of Directors | - | receipt |
| Claire de Saint Blanquat | Member of the Leadership Team, VP Legal and Corporate Affairs | - | receipt |
| Marty J. Duvall | Member of the Board of Directors | - | receipt |
| Odile Belzunce | Member of the Leadership Team, VP Compliance, IT and Portfolio Management | - | receipt |
| Olivier Martinez | Member of the Board of Directors | - | receipt |
| Pascale Boissel | Vice Chairwoman of the Board of Directors | - | receipt |
| Sally Bennett | Member of the Board of Directors | - | receipt |
| Stéphanie Cornen | Member of the Leadership Team, VP Investor Relations, Communication & Commercial Strategy | - | receipt |
familynone on file
upcomingnone on file
changesnone on file
mcp_package_hint
slug innate-pharma-s-a
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$